Research programme: caspase inhibitors - New World Laboratories

Drug Profile

Research programme: caspase inhibitors - New World Laboratories

Alternative Names: NWL 149; NWL 154; NWL 53

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator New World Laboratories
  • Class Peptides
  • Mechanism of Action Caspase 1 inhibitors; Caspase 4 inhibitors; Caspase 6 inhibitors; Caspase-3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Brain injuries; Cancer; Huntington's disease; Inflammation; Multiple sclerosis; Myocardial infarction; Parkinson's disease; Spinal cord injuries; Stroke

Most Recent Events

  • 24 Nov 2016 Research programme: caspase inhibitors - New World Laboratories is available for licensing as of 24 Nov 2016. https://nwl.net/en/partnerships/
  • 24 Nov 2016 Preclinical trials in Alzheimer's disease in Canada (unspecified route)
  • 24 Nov 2016 Preclinical trials in Brain injuries in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top